{"id":38499,"date":"2017-09-06T00:00:00","date_gmt":"2017-09-05T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/"},"modified":"2020-11-16T16:20:21","modified_gmt":"2020-11-16T15:20:21","slug":"aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/","title":{"rendered":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH"},"content":{"rendered":"<p>El inmun\u00f3geno HTI combina regiones antig\u00e9nicas espec\u00edficas del VIH, contra las cuales aquellos individuos que pueden controlar el virus sin necesidad de f\u00e1rmacos antirretrovirales habitualmente generan una potente respuesta inmunitaria de c\u00e9lulas T.<\/p>\n<p>AELIX-002 es un estudio de fase I, aleatorizado, doble ciego, controlado con placebo, en el que se evaluar\u00e1 la seguridad, tolerabilidad e inmunogenicidad de la vacuna HTI.\u00a0<\/p>\n<p>AELIX-002 \u00e9s un estudi de fase I, aleatorizado, doble cec, controlat amb placebo, en el qual s&#8217;avaluar\u00e0 la seguretat, tolerabilidad i inmunogenicidad de la vacuna HTI. Se espera que la inclusi\u00f3n en el ensayo de individuos diagnosticados tempranamente e inmediatamente tratados con TAR, optimizar\u00e1 la expansi\u00f3n de las respuestas inmunitarias asociadas a la vacuna. El ensayo se lleva a cabo en el Hospital Universitario Germans Trias i Pujol (HUGTIP) en Badalona (Catalu\u00f1a, Espa\u00f1a) y es ejecutado por investigadores del Instituto de Investigaci\u00f3n del Sida IrsiCaixa y la Fundaci\u00f3n Lucha contra el Sida<\/p>\n<p>\u201cEl estudio AELIX-002 se basa en nuestra experiencia previa con ensayos de vacunas terap\u00e9uticas contra el VIH. Nos permitir\u00e1 evaluar una nueva y prometedora vacuna\u00bb, destaca la Dra. Beatriz Mothe, investigadora principal del estudio en el HUGTIP. \u00abLa vacuna ha sido dise\u00f1ada con el objetivo de reeducar la respuesta inmunitaria de los pacientes contra sitios especialmente vulnerables del VIH, para que as\u00ed puedan controlar su infecci\u00f3n sin terapia antirretroviral\u00bb.<\/p>\n<p>\u00abEl desarrollo de una vacuna terap\u00e9utica segura y eficaz contra el VIH que libere a los pacientes de la terapia antirretroviral podr\u00eda considerarse como la \u00faltima frontera en la investigaci\u00f3n del VIH\u00bb, explica el doctor Ian McGowan, director m\u00e9dico de AELIX Therapeutics. \u00abEstamos muy contentos de poder asociarnos con la Dra. Mothe y sus colegas en la evaluaci\u00f3n de la seguridad e inmunogenicidad de nuestra vacuna HTI\u00bb.<br \/>\n\u00a0<\/p>\n<p>\u25ba M\u00e1s informaci\u00f3n en el siguiente<a href=\"http:\/\/ala.com\/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial\/\" target=\"_blank\" rel=\"noopener noreferrer\">\u00a0<\/a><a href=\"http:\/\/www.aelixtherapeutics.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">enla\u00e7e [+]<\/a><\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotecnol\u00f3gica\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/ca\/empresa?p_p_id=detallempresa_WAR_empleatsempresesportlet&amp;p_p_state=MAXIMIZED&amp;_detallempresa_WAR_empleatsempresesportlet_empresaId=ENT_006855&amp;_detallempresa_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fentitats\" target=\"_blank\" rel=\"noopener noreferrer\">Aelix Therapeutics<\/a>,\u00a0con sede en el Parc Cient\u00edfic de Barcelona y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH, ha incluido el primer paciente en el ensayo cl\u00ednico inicial para la evaluaci\u00f3n de su principal producto, el\u00a0\u00a0inmun\u00f3geno HTI\u00a0como vacuna terap\u00e9utica.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":24510,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-38499","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La biotecnol\u00f3gica\u00a0Aelix Therapeutics,\u00a0con sede en el Parc Cient\u00edfic de Barcelona y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH, ha incluido el primer paciente en el ensayo cl\u00ednico inicial para la evaluaci\u00f3n de su principal producto, el\u00a0\u00a0inmun\u00f3geno HTI\u00a0como vacuna terap\u00e9utica. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-05T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:20:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"412\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH\",\"datePublished\":\"2017-09-05T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16049214855fa9288d6765c.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/\",\"name\":\"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16049214855fa9288d6765c.jpeg\",\"datePublished\":\"2017-09-05T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16049214855fa9288d6765c.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/16049214855fa9288d6765c.jpeg\",\"width\":800,\"height\":412},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/","og_locale":"es_ES","og_type":"article","og_title":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona","og_description":"La biotecnol\u00f3gica\u00a0Aelix Therapeutics,\u00a0con sede en el Parc Cient\u00edfic de Barcelona y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH, ha incluido el primer paciente en el ensayo cl\u00ednico inicial para la evaluaci\u00f3n de su principal producto, el\u00a0\u00a0inmun\u00f3geno HTI\u00a0como vacuna terap\u00e9utica. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2017-09-05T23:00:00+00:00","article_modified_time":"2020-11-16T15:20:21+00:00","og_image":[{"width":800,"height":412,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH","datePublished":"2017-09-05T23:00:00+00:00","dateModified":"2020-11-16T15:20:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/"},"wordCount":336,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/","url":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/","name":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg","datePublished":"2017-09-05T23:00:00+00:00","dateModified":"2020-11-16T15:20:21+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/09\/16049214855fa9288d6765c.jpeg","width":800,"height":412},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-incluye-el-primer-paciente-en-el-ensayo-clinico-inicial-de-su-vacuna-terapeutica-contra-el-vih\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"AELIX Therapeutics incluye el primer paciente en el ensayo cl\u00ednico inicial de su vacuna terap\u00e9utica contra el VIH"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=38499"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38499\/revisions"}],"predecessor-version":[{"id":44627,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38499\/revisions\/44627"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/24510"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=38499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=38499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=38499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}